• AIM: To evaluate the clinical effect of bevacizumab in pterygium treatment.
INTRODUCTION

P
terygium is a chronic disease of the ocular surface, which is associated with inflammation and neovascularization.
It features the invasive centripetal proliferation of fibrovascular tissue mostly on the nasal aspect of bulbar conjunctiva. Although a number of surgical techniques have been described as methods for pteryigium treatment, including bare sclera resection, excision plus rotational conjunctival flap, and excision with conjunctival autograft placement, the recurrence rate remains high after surgery. In following discussion, the definition of pterygium recurrence referred to Tseng's criteria, which with fibrovascular tissue invading the cornea [1] . Several studies suggested vascular endothelial growth factor (VEGF) is over expressing and plays an important role in development of pterygium [2] [3] [4] . This led to the hypothesis that the application of anti-VEGF agent could be beneficial for patients with pterigium. Bevacizumab, a recombinant human monoclonal antibody against VEGF which is approved by FDA in several neoplasms therapy, showed a promising role in both retinal disease and eye surface disease by off-label use. Several clinical trials were conducted to evaluate the effect of bevacizumab in pterygium treatment. However, the outcomes were still limited and controversial. In this review, we sought to investigate whether bevacizumab could decrease the reccurence rate in pterygium patients.
MATERIALS AND METHODS Search Strategy
Articles about "pterygium OR pterygia therapy AND bevacizumab" were searched in PubMed, EMBASE, Web of Science and Cochrane Controlled Trials Register before June 2016 by two reviewers (Liu J and Liang GL) independently. Only English language articles were included. We also searched the bibliographies of retrieved articles for potentially relevant articles. Including and Excluding Criteria We included randomized controlled trials (RCTs) that met the following inclusion criteria: 1) evaluated the efficacy of bevacizumab in patients with pterygium; 2) compared with control group either negative or blank; 3) defined pterygium recurrence as fibrovascular tissue invading the cornea; 4) assessed the recurrence in the outcomes; 5) provided enough data for calculating the risk ratio (RR) and 95% confidence interval (CI); 6) the one with complete data if studies were duplicates. Exclusion criteria were: 1) duplicate research; 2) reviews, letters and comments; 3) follow-up was shorter than 3mo; 4) low quality clinical trials.
Data Abstraction and Quality Assessment Two reviewers independently retrieved the eligible studies according to the search strategy and selection criteria. The manual search was performed to retrieve some more eligible studies in the reviews and references of included studies. After article identification, characteristics of studies and patients such as first author, publication year, age and gender of patients, type of pterygium, sample size, pterygium length, intervention method, follow-up period, outcome assessment and study location were extracted independently. Discrepancies in data abstraction were resolved by referring to the original article. Study quality was assessed by Jadad scale, which contains evaluation of randomization, blinding, participant withdrawals/ dropouts. If randomization and blinding were appropriate, additional point was added for each. The quality score ranges from 0 to 5 points. When the score of article <3, it was considered to be low quality. The risk of bias in RCTs was assessed following cochranere commendations and publication bias was evaluated by Egger test (Stata version 10.0). Publication bias was indicated when P value was less than 0.1. Statistical Analysis The result was reported as a pooled RR with 95% CI. Statistical heterogeneity was tested using the χ 2 and I 2 statistic. Fixed-effects model was used by MantelHaenszel method unless significant evidence of statistical heterogeneity or clinical diversity was found. However, for result showing significant heterogeneity (I 2 >50%), a randomeffects Meta-analysis was performed by DerSimonian-Laird method [5] . P value<0.05 was considered statistically significant difference. The Meta-analysis was done consists with recommendations from the Cochrane Collaboration and the PRISMA Statement with standard software (Revman 5.0 and Stata version 10.0) [6] . The PRISMA checklist was guided the overall conduct of this study.
RESULTS
Characteristics and Quality Assessment of Eligible Studies
Up to June 2016, 54 records were finally retrieved using the search strategy and after removing duplication. Reviewing the titles and abstracts, there were 23 studies left for full text reviewed and quality assessment. With careful evaluation according to our eligibility criteria, 5 studies were excluded for without negative control [7] [8] [9] [10] [11] , 5 studies for without exact information about recurrence [12] [13] [14] [15] [16] , 2 articles for different definitions of recurrence [17] [18] and 2 articles for low quality [19] [20] . Finally, 9 controlled clinical trials with 496 participants were included in this Meta-analysis ( Figure 1 ). The main characteristics of RCTs were listed in Table 1 . The included articles were published from 2011 to 2016, originated from Thailand, Iran, Egypt, Turkey, Mexico and India. Quality assessment was conducted according to Jadad scale and Cochrane Collaboration's tool. The biases in these studies were showed in Figure 2 . Figure 6 ).
Analysis of Recurrence of Patients with Simple Pterygium Excision and Excision with Conjunctival Autograft
In all of included studies, bevacizumab was performed as adjuvant therapy with surgery such as excision with conjunctival autograft, excision with rotational conjunctival flap or excision by bare sclera technique. To avoid the influence of surgery routine, we made analysis of simple excision and excision with conjunctival autograft surgery. Pooled results showed no difference between bevacizumab intervention versus placebo/ . But at 1y follow-up, bevacizumab therapy seems to be effective in decreasing the recurrence rate [RR=0.14 (0.05, 0.36)]. However, the recurrence rate at 1y follow-up was genarated from only two studies with the small sample size. Furthermore, a number of factors such as route of administration, type of pterygium, surgical technique, age of patient and environmental agents may also have influence on pterygium recurrence. To avoid these confounding factors, we made the following subgroup analysis. The routes of bevacizumab for pterygium therapy include topical application and subconjunctival application. Our Meta-analysis showed the recurrence rates were similar in patients with subconjunctival bevacizumab application or not at 3mo and 6mo. Motarjemizadeh et al [21] shows a doseresponse relationship between the different concentrations of bevacizumab eye drops and pterygium recurrence. Conversely, several studies didn't find the does-effect on recurrence [29] . To eliminate the potential influence of dosage, we analyzed the recurrence rate in patients with 1.25 mg/0.05 mL bevacizumab subconjunctival injection. No significant different recurrence rate was observed at 3mo and 6mo either. In 3 types of pterygium, impending recurrent pterygium is more likely to progress to a true recurrence, and a recurrent pterygium is more likely to have an exuberant fibrovascular growth response [30] .
To exclude the potential influence of pterygium type, we analyzed the recurrence rate in patients with primary pterygium but found no significant difference between groups at 3mo and 6mo follow-up. Commonly used surgical techniques now contain bare sclera, excision with rotational conjunctival flap, and excision combined conjunctival autograft placement. The recurrence of pterygium is also affected by the surgical technique. To eliminate the influence of surgery technique, we analyzed the recurrence rate in patients with pterygium simple excision and excision with conjunctival autograft respectively. No difference between bevacizumab intervention versus placebo/no intervention was observed at 3mo and 6mo followup in both subgroups. In some studies, bevacizumab had a role in decreasing grade, color intensity, size of pterygium. Wu et al [31] reported that the case treated with topical bevacizumab for 3wk produced prominent regression of limbal-conjunctival neovascularization and no recurrence of pterygium was noted at 6mo. Sarac et al [32] considered that average ocular irritation score, horizontal length, and the thickness of the pterygium could significantly decreased by intralesional bevacizumab (1.25 mg/0.05 mL) administration in 33 patients. A study conducted by Fallah et al [12] proved topical bevacizumab administration (5 mg/mL) could delay the recurrence of pterygium. However, in our analysis, we didn't observe the effect of bevacizumab in short term follow-up (3mo and 6mo). Razeghinejad et al [33] got a similar conclusion by a series of studies. At first, they used a single (1.25 mg) intraoperative subconjunctival bevacizumab administration and the outcome showed no difference at 6mo follow-up. Then, to investigate whether higher concentration of bevacizumab and more than one injection would have an effect, they compared the recurrence rate of patients with 7.5 mg bevacizumab, 2.5 mg bevacizumab, and balanced salt solution. However, no significant difference was observed as well [34] .
They believed that the formation and recurrence of pterygium was related to several factors other than VEGF such as basic fibroblast growth factor (bFGF), transforming growth factorbeta (TGF-β), metal matrix proteinase-1 (MMP-1) and platelet derived growth factor [35] . So, simply block of VEGF may not enough.
To our knowledge, it is the first comprehensive review of the efficiency of bevacizumab therapy in pterygium treatment with different follow-up periods. Hu et al [36] performed an analysis about the effect of bevacizumab on pterygium. The study suggested topical or subconjunctival bevacizumab is relatively safe and well tolerated. To minimized potential selection biases and ensured accuracy of the abstracted data, we made analysis in patients with subconjunctival injection, primary pterygium, simple excision and excision with conjunctival autograft respectively. None of these analyses showed significant effect of bevacizumab in the decrease of recurrence rate. Considering the close relationship between recurrence and follow-up periods, we performed each analysis by different followup periods at different follow-up periods, but didn't find any obvious influence either. Nevertheless, our systematic review has several limitations. First, the number of included studies and participants in each subgroup analysis was relatively small. Second, the heterogeneity may be due to different type of pterygium, route of drug administration, surgeon's experience and other confounders. In order to get convinced results, more large scale of statistical data is needed.
In conclusion, the results of this Meta-analysis suggest that bevacizumab has no significant effect on the recurrence of pterygium in short term follow-up. Large scale RCTs and longterm follow-up are still needed.
